WorldCat Identities

Sakamoto, Junichi

Overview
Works: 28 works in 31 publications in 3 languages and 82 library holdings
Genres: Charts, diagrams, etc 
Roles: Author, Inventor
Publication Timeline
.
Most widely held works by Junichi Sakamoto
Policy Action in Private Occupational Pensions in Japan since the Economic Crisis of the 1990s by Labour and Welfare, Japan Ministry of Health( )

2 editions published in 2010 in English and held by 26 WorldCat member libraries worldwide

The public pension system of Japan provides coverage for all, irrespective of occupation and income. Corporate pension plans provide additional benefits over the public pension in order to meet the diversified financial needs in retirement and play a key role in enriching people‘s life after retirement. The majority of corporate pensions in Japan are defined-benefit type. Consequently, a great amount of attention is paid to benefit rights. Nevertheless, in order to avoid the discontinuation of pension plans due to over-emphasis on benefit rights, Japan introduced a measure under the stagnant economy during the 1990s allowing pension plans to reduce accrued benefits under certain strict conditions, only when the government acknowledges that the sponsoring company will go bankrupt if employers are forced to continue to contribute to the pension plans to the same extent. At the same time, Japan introduced another measure allowing pension plans to use smoothing for valuing its assets in order to avoid temporary market fluctuations. As a result, corporate pension plans in Japan became manageable from a long-term perspective and able to adopt a flexible plan design whilst still ensuring benefit rights
Policy Action in Private Occupational Pensions in Japan since the Economic Crisis of the 1990s by Labour and Welfare, Japan Ministry of Health( )

1 edition published in 2010 in English and held by 23 WorldCat member libraries worldwide

The public pension system of Japan provides coverage for all, irrespective of occupation and income. Corporate pension plans provide additional benefits over the public pension in order to meet the diversified financial needs in retirement and play a key role in enriching people's life after retirement. The majority of corporate pensions in Japan are defined-benefit type. Consequently, a great amount of attention is paid to benefit rights. Nevertheless, in order to avoid the discontinuation of pension plans due to over-emphasis on benefit rights, Japan introduced a measure under the stagnant economy during the 1990s allowing pension plans to reduce accrued benefits under certain strict conditions, only when the government acknowledges that the sponsoring company will go bankrupt if employers are forced to continue to contribute to the pension plans to the same extent. At the same time, Japan introduced another measure allowing pension plans to use smoothing for valuing its assets in order to avoid temporary market fluctuations. As a result, corporate pension plans in Japan became manageable from a long-term perspective and able to adopt a flexible plan design whilst still ensuring benefit rights
Riometer records of 30 MHz cosmic noise at Syowa Station, Antarctica in 1977 by M Ose( Book )

3 editions published in 1978 in English and held by 8 WorldCat member libraries worldwide

Japan : pension reform and funding options by J Sakamoto( )

1 edition published in 2001 in German and held by 2 WorldCat member libraries worldwide

Unifying pension schemes in Japan : toward a single scheme for both civil servants and private employees by J Sakamoto( Book )

1 edition published in 2008 in English and held by 1 WorldCat member library worldwide

Safety matches trade mark( Book )

in English and held by 1 WorldCat member library worldwide

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Thymic epithelial tumors are rare malignancies, and no optimal therapeutic regimen has been defined for patients with advanced disease. Patients with advanced thymic epithelial tumors, which were resistant or intolerable to prior therapies, were eligible for this study. Patients received 9 mer‐WT1‐derived peptide emulsified with Montanide ISA51 adjuvant via intradermal administration once a week as a monotherapy. After the 3‐month‐protocol treatment, the treatment was continued mostly at intervals of 2–4 weeks until disease progression or intolerable adverse events occurred. Of the 15 patients enrolled, 11 had thymic carcinoma (TC) and 4 had invasive thymoma (IT). Median period from diagnosis to the start of treatment was 13.3 and 65.5 months for TC and IT, respectively. No patients achieved a complete or partial response. Of the 8 evaluable TC patients, 6 (75.0%) had stable disease (SD) and 2 had progressive disease (PD). Of the 4 evaluable IT patients, 3 (75.0%) had SD and 1 (25.0%) had PD. Median period of monotherapy treatment was 133 and 683 days in TC and IT patients, respectively. No severe adverse events occurred during the 3‐month‐protocol treatment. As adverse events in long responders, thymoma‐related autoimmune complications, pure red cell aplasia and myasthenia gravis occurred in two IT patients. Cerebellar hemorrhage developed in a TC patient complicated with Von Willebrand disease. Induction of WT1‐specific immune responses was observed in the majority of the patients. WT1 peptide vaccine immunotherapy may have antitumor potential against thymic malignancies. Abstract : What's new? Because it is overexpressed in many types of cancer, the protein WT1 is a promising target for cancer immunotherapy. In this phase II clinical trial in advanced thymic cancers, the authors tested the efficacy of vaccinating patients with a WT1 peptide. While this did not shrink the tumors, 75% of patients maintained stable disease over several months. Because thymic tumors often go undetected until an advanced stage, WT1 immunotherapy may offer a useful adjunct approach in these difficult cancers
Method of producing polyester that contains fluorine compound particles( Book )

in English and held by 1 WorldCat member library worldwide

Low-calorie mayonnaise-like food( Book )

in English and held by 1 WorldCat member library worldwide

Three stars safety matches( Book )

in English and held by 1 WorldCat member library worldwide

Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study)( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract Aim This prospective multicenter study aimed to evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy (HAIC) using percutaneous catheter placement techniques for liver metastases from colorectal cancer (CRC). Methods We administered 5‐fluorouracil at 1000 mg/m2 over 5 h via hepatic arterial infusion on a weekly schedule. The primary endpoint was the overall response rate (RR). The secondary endpoints were the overall survival (OS), progression‐free survival (PFS) and toxicities. Results Between February 2000 and March 2002, seventy‐seven eligible patients were enrolled in this study. After a median of 26 treatment cycles, 4 patients achieved a complete response, 29 achieved a partial response, 28 had stable disease, 15 had progressive disease and the status of one patient was unknown. The overall RR was 42.9% and the disease control rate (DCR) was 79.2%. The median PFS and OS times were 203 and 560 days, respectively. The most common grade 3 or 4 hematological and non‐hematological toxicities were total bilirubin level elevation (10.4%) and gamma‐glutamyl transferase level elevation (10.4%). With regard to the relationship between the background factors and treatment outcomes, the DCR, RR, PFS and OS were different between patients with and without extrahepatic lesions (DCR: 86.5% vs 64%, RR: 46.2% vs 36.0%, PFS: 233 days vs 99 days, OS: 587 days vs 558 days). Conclusion The primary endpoint of this study was not met. HAIC using percutaneous catheter placement techniques did not improve the RR for liver metastasis from CRC
Thermoplastic polyester composites( Book )

in English and held by 1 WorldCat member library worldwide

A Phase I/II Study of XELIRI Plus Bevacizumab as Second‐Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

Abstract : Background: Capecitabine is used mainly with oxaliplatin to treat metastatic colorectal cancer (mCRC). Results from capecitabine plus irinotecan (XELIRI) with or without bevacizumab (BV) have been reported in Europe but not in Japan. Consequently, the safety and efficacy of XELIRI plus BV in Japanese patients with mCRC were assessed in a single‐arm phase II study. Methods: Eligible patients had had prior chemotherapy containing BV for mCRC and wild‐type or heterozygous UGT1A1. Therapy in each 21‐day treatment cycle consisted of capecitabine (800 mg/m 2 twice daily on days 1–15), irinotecan (200 mg/m 2 on day 1), and BV (7.5 mg/kg on day 1). The primary endpoint was dose‐limiting toxicity in phase I and progression‐free survival (PFS) in phase II. Results: A total of 34 patients (6 in phase I, 28 in phase II) were enrolled from May 2010 to June 2011. Baseline characteristics included a median age of 60 years (range: 22–74 years) for 24 men and 10 women. No dose‐limiting toxicities appeared in phase I. Median PFS was 240 days (95% confidence interval: 179–311 days). Overall response rate was 18.1%, and the disease‐control rate was 90.9%. The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55.9%; grade 3 or 4, 11.8%), diarrhea (any grade, 50%; grade 3 or 4, 5.9%), and hand‐foot syndrome (any grade, 61.8%; grade 3 or 4, 5.9%). Conclusion: Our results suggest that XELIRI plus BV is well tolerated and effective as a second‐line treatment for mCRC in Japanese patients. This regimen could be especially appropriate for patients resistant to oxaliplatin‐based regimens
Trends and Barriers to HIV Testing Among Tuberculosis Patients in Prey Kabas Operational District, Takeo Province, Cambodia( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Data for this study were obtained from 2375 tuberculosis (TB) patients registered during 2007-2009 and 43 health providers to examine the trend of TB patient referral for HIV (human immunodeficiency virus) testing and to investigate provider-associated barriers to the referral in Prey Kabas operational district, Takeo province, Cambodia. Referral rate for HIV testing was 4.4% (30/684) in 2007, 15.4% (116/751) in 2008, and 30.1% (283/940) in 2009, with a significant upward trend over the period of time ( P = .009). The main barriers perceived by health providers were poor knowledge about TB/HIV, lack of communication skills, absence of any target plan for TB patient referral for HIV testing, and fear associated with informing positive test results to the TB patients and the associated stigma. Strategies to raise awareness about HIV/AIDS/TB among TB patients and their providers may improve the current state of low referral and its barriers in Cambodia
Best quality( Book )

in English and held by 1 WorldCat member library worldwide

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: The aim of the present study was to determine whether or not the overall survival (OS) and disease-free survival (DFS) were affected by the tumor location in patients who underwent curative resection for colon cancer in a pooled analysis of three large phase III studies performed in Japan. In total, 4029 patients were included in the present study. Patients were classified as having right-side colon cancer (RC) if the primary tumor was located in the cecum, ascending colon, hepatic flexure or transverse colon, and left-side colon cancer (LCC) if the tumor site was within the splenic flexure, descending colon, sigmoid colon or recto sigmoid junction. The risk factors for the OS and DFS were analyzed. In the present study, 1449 patients were RC, and 2580 were LCC. The OS rates at 3 and 5 years after surgery were 87.6% and 81.6% in the RC group and 91.5% and 84.5% in the LCC group, respectively. Uni- and multivariate analyses showed that RRC increased the risk of death by 19.7% (adjusted hazard ratio = 1.197; 95% confidence interval, 1.020-1.408; P = 0.0272). In contrast, the DFS was similar between the two locations. The present study confirmed that the tumor location was a risk factor for the OS in patients who underwent curative treatment for colon cancer. Tumor location may, therefore, need to be considered a stratification factor in future phase III trials of colon cancer. Abstract : The present study confirmed that the tumor location was a risk factor for the OS in patients who underwent curative treatment for colon cancer. Tumor location may, therefore, need to be considered a stratification factor in future phase III trials of colon cancer
Identification and Characterization of a New Series of Ghrelin O-Acyl Transferase Inhibitors( )

in English and held by 1 WorldCat member library worldwide

Ghrelin O-acyl transferase (GOAT; MBOAT4) catalyzes O-acylation at serine-3 of des-acyl ghrelin. Acyl ghrelin is secreted by stomach X/A-like cells and plays a role in appetite and metabolism. Therefore, GOAT has been expected to be a novel antiobesity target because it is responsible for acyl ghrelin production. Here, we report homogeneous time-resolved fluorescence (HTRF) and enzyme-linked immunosorbent assay (ELISA) methods utilizing human GOAT-expressing microsomes as a novel high-throughput assay system for the discovery of hit compounds and optimization of lead compounds. Hit compounds exemplified by compound A (2-[(2,4-dichlorobenzyl)sulfanyl]-1,3-benzoxazole-5-carboxylic acid) were identified by high-throughput screening using the HTRF assay and confirmed to have GOAT inhibitory activity using the ELISA. Based on the hit compound information, the novel lead compound (compound B, (4-chloro-6-{[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methoxy}-1-benzothiophen-3-yl)acetic acid) was synthesized and exhibited potent GOAT inhibition with oral bioavailability. Both the hit compound and lead compound showed octanoyl-CoA competitive inhibitory activity. Moreover, these two compounds decreased acyl ghrelin production in the stomach of mice after their oral administration. These novel findings demonstrate that GOAT is a druggable target, and its inhibitors are promising antiobesity drugs
Civil service pension arrangements in Japan by J Sakamoto( )

in English and held by 1 WorldCat member library worldwide

A paper presented to the International Workshop on Civil Service and Military Pension Arrangements in Selected Countries of the Asia-Pacific organized by PIE, Hitotsubashi University supported by RIPPA held at Hitotsubashi Collaboration Center, Tokyo, Japan on 20-21 January 2011
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.84 (from 0.56 for Best quali ... to 0.99 for Thermoplas ...)

Associated Subjects
Alternative Names
Sakamoto, Junʼichi.

Languages